MedWatch

FDA accepts Eli Lilly application for supplemental use of diabetes drug

Eli Lilly has sent supplemental new drug application to US FDA for use of diabetes drug Jardiance.

The US Food and Drug Administration has confirmed receipt of Eli Lilly's application to supplement the use of the diabetes drug Jardiance, according to a Monday press release.

Now it is up to the FDA to decide whether Jardiance can indeed be used as a treatment to reduce the risk of cardiovascular death and the risk of ending up in hospital in cases of heart failure. It will further look at whether the drug can be used to slow kidney function decline in adults with chronic heart failure – both in patients with and without type II diabetes.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles